Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Bioenerg Biomembr ; 56(5): 531-542, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39083188

RESUMEN

The current study explored melatonin (MEL) and its receptors, including MEL type 1 receptor (MT1) receptor and MEL type 2 receptor (MT2), along with the angiotensin-converting enzyme 2 (ACE2), influence on vascular responses to angiotensin II (Ang II) in rat aortic segments of normal and diabetic rats. The isolated aortic segments were exposed to MEL, the MEL agonist; ramelteon (RAM), the MEL antagonist; luzindole (LUZ), and an ACE2 inhibitor (S, S)-2-(1-Carboxy-2-(3-(3,5-dichlorobenzyl)-3 H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid,) on Ang II-induced contractions in non-diabetic normal endothelium (non-DM E+), non-diabetic removed endothelium (non-DM E-), and streptozotocin-induced diabetic endothelium-intact (STZ-induced DM E+) rat aortic segments, as well as their combination in STZ-induced DM E + segments, were also included. The current results showed that MEL and RAM shifted Ang II dose-response curve (DRC) to the right side in non-DM E + and non-DM E- aorta but not in STZ-induced DM E + aorta. However, ACE2 inhibition abolished Ang II degradation only in STZ-induced DM E + segments, not in non-DM E + segments. Additionally, the combinations of MEL-LUZ and RAM-ACE2 inhibitor caused a rightward shift in Ang II response in STZ-induced DM E + segments, while the MEL-LUZ combination decreased Ang II DRC. The findings suggest that the effects of MEL and ACE2 inhibitor on Ang II responses depend on the condition of the endothelium and the distribution of the MEL receptors.


Asunto(s)
Angiotensina II , Aorta , Diabetes Mellitus Experimental , Endotelio Vascular , Melatonina , Animales , Melatonina/farmacología , Angiotensina II/farmacología , Ratas , Endotelio Vascular/metabolismo , Endotelio Vascular/efectos de los fármacos , Masculino , Aorta/efectos de los fármacos , Aorta/metabolismo , Enzima Convertidora de Angiotensina 2/metabolismo , Ratas Wistar
2.
J Recept Signal Transduct Res ; 44(1): 35-40, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38666646

RESUMEN

BACKGROUND: The pineal product melatonin (MEL) modulates blood vessels through G protein-coupled receptors (GPCRs) called melatonin type 1 receptor (MT1R) and melatonin type 2 receptor (MT2R), in that order. The renin-angiotensin system (RAS), which breaks down angiotensin II (Ang II) to create Ang 1-7, is thought to be mostly controlled by angiotensin-converting enzyme-2 (ACE2). AIM: The current work examines the involvement of ACE2 inhibitor, MEL, and ramelteon (RAM) in the vascular response to Ang II activities in the endothelial denuded (E-) and intact (E+) rat isolated thoracic aortic rings. METHOD: The isometric tension was measured to evaluate the vascular Ang II contractility using dose response curve (DRC). RESULTS: MEL and RAM caused a rightward shift of Ang II in endothelium E + and endothelium E- aorta. CONCLUSION: According to the current study, the distribution of MEL receptors and the endothelium's condition are related to the vasomodulatory effect of MEL and ACE2 on Ang II attenuation. These physiological interactions can control vascular tone and increase Ang II reactivity denude endothelial layaer.


Asunto(s)
Angiotensina II , Enzima Convertidora de Angiotensina 2 , Melatonina , Animales , Melatonina/farmacología , Angiotensina II/metabolismo , Angiotensina II/farmacología , Ratas , Enzima Convertidora de Angiotensina 2/metabolismo , Sistema Renina-Angiotensina/efectos de los fármacos , Aorta Torácica/efectos de los fármacos , Aorta Torácica/metabolismo , Masculino , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Peptidil-Dipeptidasa A/metabolismo , Aorta/efectos de los fármacos , Aorta/metabolismo , Receptor de Melatonina MT2/metabolismo , Receptor de Melatonina MT2/antagonistas & inhibidores , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología
3.
Exp Ther Med ; 21(3): 214, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33500703

RESUMEN

Recent studies have focused on the role of gasotransmitters in cancer progression and prevention. Therefore, the current study was designed to explore the vasodilator activity of NO and H2S in the human mesenteric arteries of patients with colorectal cancer (CRC) via the activation of K+ channels. A total of two sets of experiments were established for the current investigation. Blood samples from patients with CRC were obtained to detect serum levels of endocan and malondialdehyde (MDA). The role of K+ channels in mediating the vasodilation of the human mesenteric artery in response to sodium nitroprusside (SNP) and sodium disulfide (Na2S) was assessed. The level of serum endocan was indicated to be decreased in patients with CRC compared with healthy individuals, while the level of serum MDA remained unaltered between groups. The arterial rings pre-contracted with norepinephrine were first relaxed by the cumulative addition of increasing concentrations of either SNP (30 nM-30 µM) or (1-6 mM). Maximal relaxation rates were then calculated at 15 min intervals for 60 min. Pre-incubation of arterial rings for 20 min with individual K+ channel blockers was indicated to significantly reduce SNP- and Na2S-induced relaxation at different time points. Pre-treatment of L-nitro-arginine methyl ester did not alter vasodilation that was induced by Na2S. Furthermore, vasodilation of the CRC mesenteric artery was not altered by the synergistic application of SNP and Na2S, while pre-incubation of arterial rings with D,L-propargylglycine significantly enhanced vasodilation induced by SNP. These results indicated that endothelial dysfunction and oxidative stress do not serve roles in the pathogenesis of CRC. The dilatory mechanisms of NO and H2S in mesenteric arteries of patients with CRC were K+ channel- and time-dependent, and the activity of cystathionine γ-lyase enzyme inhibited the ability of exogenous NO in vasodilation processes.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA